Share：
Share this content in WeChat
X
[Chinese] [PDF] 5 1
• Reviews •
Application and progress of nigral imaging in the early diagnosis of Parkinson's disease
HUANG Yingmeng  PENG Yongjun 

Cite this article as: HUANG Y M, PENG Y J. Application and progress of nigral imaging in the early diagnosis of Parkinson's disease[J]. Chin J Magn Reson Imaging, 2026, 17(3): 155-160, 173 DOI:10.12015/issn.1674-8034.2026.03.022.


[Abstract] Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders, primarily characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta. Early diagnosis of PD is crucial for timely therapeutic intervention and improved clinical outcomes. MRI, as a non-invasive imaging modality, has shown great promise in the early detection of PD, particularly in evaluating structural and functional alterations in the substantia nigra. This review highlights four representative MRI techniques used to assess the substantia nigra in early-stage PD: Nigrosome imaging, neuromelanin-sensitive MRI, quantitative susceptibility mapping, and diffusion tensor imaging. We systematically discuss the imaging principles, recent research advancements, and the diagnostic performance and limitations of each technique in detecting early PD. Moreover, we explore the utility of these imaging approaches in the differential diagnosis of atypical Parkinsonian syndromes. Finally, we outline potential future research directions and clinical applications, aiming to provide theoretical foundations and technical support for advancing the early diagnosis of PD.
[Keywords] Parkinson's disease；magnetic resonance imaging；substantia nigra imaging；early diagnosis；Parkinsonism

HUANG Yingmeng   PENG Yongjun*  

Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital, the Affiliated Hospital of Beijing Institute of Technology), Zhuhai 519000, China

Corresponding author: PENG Y J, E-mail: yongjunpeng@ext.jnu.edu.cn

Conflicts of interest   None.

Received  2025-10-22
Accepted  2026-01-05
DOI: 10.12015/issn.1674-8034.2026.03.022
Cite this article as: HUANG Y M, PENG Y J. Application and progress of nigral imaging in the early diagnosis of Parkinson's disease[J]. Chin J Magn Reson Imaging, 2026, 17(3): 155-160, 173 DOI:10.12015/issn.1674-8034.2026.03.022.

[1]
BEN-SHLOMO Y, DARWEESH S, LLIBRE-GUERRA J, et al. The epidemiology of Parkinson's disease[J]. Lancet (lond. Engl), 2024, 403(10423): 283-292. DOI: 10.1016/S0140-6736(23)01419-8.
[2]
SU D, CUI Y, HE C, et al. Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021[J/OL]. BMJ, 2025, 388: e080952 [2025-10-22]. https://doi.org/10.1136/bmj-2024-080952. DOI: 10.1136/bmj-2024-080952.
[3]
KALIA L V, BERG D, KORDOWER J H, et al. International Parkinson and movement disorder society viewpoint on biological frameworks of Parkinson's disease: current status and future directions[J]. Mov Disord, 2024, 39(10): 1710-1715. DOI: 10.1002/mds.30007.
[4]
TANNER C M, OSTREM J L. Parkinson's disease[J]. N. Engl J Med, 2024, 391(5): 442-452. DOI: 10.1056/NEJMra2401857.
[5]
TOLOSA E, GARRIDO A, SCHOLZ S W, et al. Challenges in the diagnosis of Parkinson's disease[J]. The Lancet Neurol, 2021, 20(5): 385-397. DOI: 10.1016/S1474-4422(21)00030-2.
[6]
WANG X, ZHANG Y, ZHU C, et al. The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis[J]. Neurol Sci, 2019, 40(12): 2479-2489. DOI: 10.1007/s10072-019-04014-y.
[7]
MORRIS H R, SPILLANTINI M G, SUE C M, et al. The pathogenesis of Parkinson's disease[J]. Lancet (lond. Engl), 2024, 403(10423): 293-304. DOI: 10.1016/S0140-6736(23)01478-2.
[8]
DAMIER P, HIRSCH E C, AGID Y, et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease[J]. Brain, 1999, 122(Pt 8): 1437-1448. DOI: 10.1093/brain/122.8.1437.
[9]
TSERIOTIS V S, ELEFTHERIADOU K, MAVRIDIS T, et al. Is the swallow tail sign a useful imaging biomarker in clinical neurology? A systematic review[J]. Mov Disord Clin Pract, 2025, 12(2): 134-147. DOI: 10.1002/mdc3.14304.
[10]
CHAU M T, TODD G, WILCOX R, et al. Diagnostic accuracy of the appearance of nigrosome-1 on magnetic resonance imaging in Parkinson's disease: a systematic review and meta-analysis[J]. Parkinsonism Relat Disord, 2020, 78: 12-20. DOI: 10.1016/j.parkreldis.2020.07.002.
[11]
FERACO P, GAGLIARDO C, LA TONA G, et al. Diagnostic performance of loss of nigral hyperintensity on susceptibility-weighted imaging in Parkinsonism: an updated meta-analys[J/OL]. Brain Sci, 2021, 11(6): 769 [2025-10-22]. https://doi.org/10.3390/brainsci11060769. DOI: 10.3390/brainsci11060769.
[12]
WELTON T, HARTONO S, SHIH Y C, et al. Ultra-high-field 7T MRI in Parkinson's disease: ready for clinical use?—a narrative review[J]. Quant Imaging Med Surg, 2023, 13(11): 7607-7620. DOI: 10.21037/qims-23-509.
[13]
ZHANG X, CHAI C, GHASSABAN K, et al. Assessing brain iron and volume of subcortical nuclei in idiopathic rapid eye movement sleep behavior disorder[J/OL]. Sleep, 2021, 44(10): zsab131 [2025-10-22]. https://doi.org/10.1093/sleep/zsab131. DOI: 10.1093/sleep/zsab131.
[14]
CHAU M T, AGZARIAN M, WILCOX R A, et al. Simple quantitative planimetric measurement of nigrosome-1 for clinical settings[J/OL]. J Neurol Sci, 2023, 454: 120857 [2025-10-22]. https://doi.org/10.1016/j.jns.2023.120857. DOI: 10.1016/j.jns.2023.120857.
[15]
CHEN Y, GONG T, SUN C, et al. Regional age-related changes of neuromelanin and iron in the substantia nigra based on neuromelanin accumulation and iron deposition[J]. Eur Radio, 2023, 33(5): 3704-3714. DOI: 10.1007/s00330-023-09411-8.
[16]
SASAKI M, SHIBATA E, KUDO K, et al. Neuromelanin-Sensitive MRI[J]. Clin. Neuroradiol, 2008, 18(3): 147-153. DOI: 10.1007/s00062-008-8018-4.
[17]
PRIOVOULOS N, VAN BOXEL S C J, JACOBS H I L, et al. Unraveling the contributions to the neuromelanin-MRI contrast[J]. Brain Struct. Funct, 2020, 225(9): 2757-2774. DOI: 10.1007/s00429-020-02153-z.
[18]
YAN Y, ZHANG M, REN W, et al. Neuromelanin-sensitive magnetic resonance imaging: Possibilities and promises as an imaging biomarker for Parkinson's disease[J]. Eur J Neurosci, 2024, 59(10): 2616-2627. DOI: 10.1111/ejn.16296.
[19]
LAKHANI D A, ZHOU X, TAO S, et al. Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson's disease[J/OL]. npj Parkinson's Dis, 2024, 10: 13 [2025-10-22]. https://doi.org/10.1038/s41531-024-00631-3. DOI: 10.1038/s41531-024-00631-3.
[20]
BIONDETTI E, GAURAV R, YAHIA-CHERIF L, et al. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease[J]. J Neurol, 2020, 143(9): 2757-2770. DOI: 10.1093/brain/awaa216.
[21]
LIU Q, WANG P, LIU C, et al. An investigation of neuromelanin distribution in substantia nigra and locus coeruleus in patients with Parkinson's disease using neuromelanin-sensitive MRI[J/OL]. BMC Neurol, 2023, 23(1): 301 [2025-10-22]. https://doi.org/10.1186/s12883-023-03350-z. DOI: 10.1186/s12883-023-03350-z.
[22]
ZENG W, CAI J, ZHANG L, et al. Iron deposition in Parkinson's disease: a mini-review[J/OL]. Cell Mol Neurobiol, 2024, 44(1): 26 [2025-10-22]. https://doi.org/10.1007/s10571-024-01459-4. DOI: 10.1007/s10571-024-01459-4.
[23]
ALUSHAJ E, HANDFIELD-JONES N, KUURSTRA A, et al. Increased iron in the substantia nigra pars compacta identifies patients with early Parkinson'sdisease: a 3T and 7T MRI study[J/OL]. Neuroimage Clin, 2024, 41: 103577 [2025-10-22]. https://doi.org/10.1016/j.nicl.2024.103577. DOI: 10.1016/j.nicl.2024.103577.
[24]
HEIM B, KRISMER F, DE MARZI R, et al. Magnetic resonance imaging for the diagnosis of Parkinson's disease[J]. J Neural Transm (Vienna), 2017, 124(8): 915-964. DOI: 10.1007/s00702-017-1717-8.
[25]
LIM S J, SUH C H, SHIM W H, et al. Diagnostic performance of T2* gradient echo, susceptibility-weighted imaging, and quantitative susceptibility mapping for patients with multiple system atrophy-Parkinsonian type: a systematic review and meta-analysis[J]. Eur Radio, 2022, 32(1): 308-318. DOI: 10.1007/s00330-021-08174-4.
[26]
KANG J J, CHEN Y, XU G D, et al. Combining quantitative susceptibility mapping to radiomics in diagnosing Parkinson's disease and assessing cognitive impairment[J]. Eur Radio, 2022, 32(10): 6992-7003. DOI: 10.1007/s00330-022-08790-8.
[27]
YAN S, LU J, DUAN B, et al. Quantitative susceptibility mapping of multiple system atrophy and Parkinson's disease correlates with neurotransmitter reference maps[J/OL]. Neurobiol Dis, 2024, 198: 106549 [2025-10-22]. https://doi.org/10.1177/17562864221143834. DOI: 10.1016/j.nbd.2024.106549.
[28]
TAN S, HARTONO S, WELTON T, et al. Utility of quantitative susceptibility mapping and diffusion kurtosis imaging in the diagnosis of early Parkinson's disease[J/OL]. Neuroimage Clin, 2021, 32: 102831 [2025-10-22]. https://doi.org/10.1016/j.nicl.2021.102831. DOI: 10.1016/j.nicl.2021.102831.
[29]
ZHAO H, JI Q H, JIA Z Z, et al. Association between deep gray matter iron deposition and clinical symptoms in Parkinson's disease: a quantitative susceptibility mapping study[J/OL]. Front Neurol, 2024, 15: 1442903 [2025-10-22]. https://doi.org/10.3389/fneur.2024.1442903. DOI: 10.3389/fneur.2024.1442903.
[30]
GUAN X, LANCIONE M, AYTON S, et al. Neuroimaging of Parkinson's disease by quantitative susceptibility mapping[J/OL]. Neuroimage, 2024, 289: 120547 [2025-10-22]. https://doi.org/10.1016/j.neuroimage.2024.120547. DOI: 10.1016/j.neuroimage.2024.120547.
[31]
NEPOZITEK J, VARGA Z, DOSTALOVA S, et al. Magnetic susceptibility changes in the brainstem reflect REM sleep without atonia severity in isolated REM sleep behavior disorder[J/OL]. npj Parkinson's Dis, 2023, 9(1): 112 [2025-10-22]. https://doi.org/10.1038/s41531-023-00557-2. DOI: 10.1038/s41531-023-00557-2.
[32]
JIN J, SU D, ZHANG J, et al. Iron deposition in subcortical nuclei of Parkinson's disease: a meta-analysis of quantitative iron-sensitive magnetic resonance imaging studies[J]. Chin Med J (Engl), 2025, 138(6): 678-692. DOI: 10.1097/CM9.0000000000003167.
[33]
JIANG S, SHAO H, ABDURAHMAN·A, et al. Evaluation of Brain Iron Deposition in Early and Advanced Patients with Parkinson's Disease Using Quantitative Susceptibility Mapping[J]. Chin Comput Med Imag, 2022, 28(4): 337-341. DOI: 10.19627/j.cnki.cn31-1700/th.2022.04.009.
[34]
SHIBATA H, UCHIDA Y, INUI S, et al. Machine learning trained with quantitative susceptibility mapping to detect mild cognitive impairment in Parkinson's disease[J]. Parkinsonism Relat Disord, 2022, 94: 104-110. DOI: 10.1016/j.parkreldis.2021.12.004.
[35]
NAKASHIMA M, KAN H, KAWAI T, et al. Quantitative susceptibility mapping analyses of white matter in Parkinson's disease using susceptibility separation technique[J/OL]. Parkinsonism Relat Disord, 2024, 128: 107135 [2025-10-22]. https://doi.org/10.1016/j.parkreldis. DOI: 10.1016/j.parkreldis.2024.107135.
[36]
NATHOO N, GEE M, NELLES K, et al. Quantitative susceptibility mapping changes relate to gait issues in Parkinson's disease[J]. Can J Neurol Sci, 2023, 50(6): 853-860. DOI: 10.1017/cjn.2022.316.
[37]
GUAN X, GUO T, ZHOU C, et al. Asymmetrical nigral iron accumulation in Parkinson's disease with motor asymmetry: an explorative, longitudinal and test-retest study[J]. Aging (Milano), 2020, 12(18): 18622-18634. DOI: 10.18632/aging.103870.
[38]
SHIH Y C, TSENG W Y I, MONTASER-KOUHSARI L. Recent advances in using diffusion tensor imaging to study white matter alterations in Parkinson's disease: a mini review[J/OL]. Front. Aging Neurosci, 2023, 14 [2025-10-22]. https://doi.org/10.3389/fnagi.2022.1018017. DOI: 10.3389/fnagi.2022.1018017.
[39]
ATKINSON-CLEMENT C, PINTO S, EUSEBIO A, et al. Diffusion tensor imaging in Parkinson's disease: review and meta-analysis[J]. Neuroimage, Clin, 2017, 16: 98-110. DOI: 10.1016/j.nicl.2017.07.011.
[40]
BAE Y J, KIM J M, SOHN C H, et al. Imaging the substantia nigra in Parkinson disease and other Parkinsonian syndromes[J]. Radiology, 2021, 300(2): 260-278. DOI: 10.1148/radiol.2021203341.
[41]
ZHANG Y, BUROCK M A. Diffusion tensor imaging in Parkinson's disease and Parkinsonian syndrome: a systematic review[J/OL]. Front. Neurol, 2020, 11: 531993 [2025-10-22]. https://doi.org/10.3389/fneur.2020.531993. DOI: 10.3389/fneur.2020.531993.
[42]
DE OLIVEIRA R V, PEREIRA J S. Utility of manual fractional anisotropy measurements in the management of patients with Parkinson disease: a feasibility study with a 1.5-T magnetic resonance imaging system[J/OL]. Acta Radiol Open, 2021, 10(2): 2058460121993477 [2025-10-22]. https://doi.org/10.1177/2058460121993477. DOI: 10.1177/2058460121993477.
[43]
SCAMARCIA P G, AGOSTA F, SPINELLI E G, et al. Longitudinal white matter damage evolution in Parkinson's disease[J]. Mov Disord, 2022, 37(2): 315-324. DOI: 10.1002/mds.28864.
[44]
BERGAMINO M, KEELING E G, MISHRA V R, et al. Assessing White Matter Pathology in Early-Stage Parkinson Disease Using Diffusion MRI: A Systematic Review[J/OL]. Front Neurol, 2020, 11: 314 [2025-10-22]. https://doi.org/10.3389/fneur.2020.00314. DOI: 10.3389/fneur.2020.00314.
[45]
OWENS-WALTON C, NIR T M, AL-BACHARI S, et al. A worldwide study of white matter microstructural alterations in people living with Parkinson's disease[J/OL]. npj Parkinson's Dis, 2024, 10(1): 151 [2025-10-22]. https://doi.org/10.1038/s41531-024-00758-3. DOI: 10.1038/s41531-024-00758-3.
[46]
LANGLEY J, HUDDLESTON D E, MERRITT M, et al. Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited[J]. Hum Brain Mapp, 2016, 37(7): 2547-2556. DOI: 10.1002/hbm.23192.
[47]
SALMINEN L E, CONTURO T E, BOLZENIUS J D, et al. Reducing csf partial volume effects to enhance diffusion tensor imaging metrics of brain microstructure[J]. Technol Innov, 2016, 18(1): 5-20. DOI: 10.21300/18.1.2016.5.
[48]
KAMAGATA K, ANDICA C, KATO A, et al. Diffusion magnetic resonance imaging-based biomarkers for neurodegenerative diseases[J/OL]. Int J Mol Sci, 2021, 22(10): 5216 [2025-10-22]. https://doi.org/10.3390/ijms22105216. DOI: 10.3390/ijms22105216.
[49]
WELTON T, HARTONO S, SHIH Y C, et al. Microstructure of Brain Nuclei in Early Parkinson's Disease: Longitudinal Diffusion Kurtosis Imaging[J]. J Parkinsons Dis, 2023, 13(2): 233-242. DOI: 10.3233/JPD-225095.
[50]
RONG Y, XU Z, ZHU Y, et al. Combination of quantitative susceptibility mapping and diffusion kurtosis imaging provides potential biomarkers for early-stage Parkinson's disease[J]. ACS Chem. Neurosci, 2022, 13(18): 2699-2708. DOI: 10.1021/acschemneuro.2c00321.
[51]
LANGLEY J, HUDDLESTON D E, HU X. Nigral diffusivity, but not free water, correlates with iron content in Parkinson's disease[J/OL]. Brain Commun, 2021, 3(4): fcab251 [2025-10-22]. https://doi.org/10.1093/braincomms/fcab251. DOI: 10.1093/braincomms/fcab251.
[52]
SHAH A, PRASAD S, INDORIA A, et al. Free water imaging in Parkinson's disease and atypical Parkinsonian disorders[J]. J Neurol, 2024, 271(5): 2521-2528. DOI: 10.1007/s00415-024-12184-9.
[53]
ZHOU G, REN J, RONG D, et al. Monitoring substantia nigra degeneration using free water imaging across prodromal and clinical Parkinson's disease[J]. Mov Disord, 2023, 38(5): 774-782. DOI: 10.1002/mds.29366.
[54]
KAMAGATA K, HATANO T, OKUZUMI A, et al. Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease[J]. Eur Radio, 2016, 26(8): 2567-2577. DOI: 10.1007/s00330-015-4066-8.
[55]
BAI X, GUO T, GUAN X, et al. Cortical microstructural alterations in different stages of Parkinson's disease[J]. Brain Imaging Behav, 2024, 18(6): 1438-1447. DOI: 10.1007/s11682-024-00931-5.
[56]
JO S, SUH C H, LEE S, et al. Susceptibility map-weighted MRI can distinguish tremor-dominant Parkinson's disease from essential tremor[J/OL]. Sci Rep, 2025, 15: 823 [2025-10-22]. https://doi.org/10.1038/s41598-024-81089-4. DOI: 10.1038/s41598-024-81089-4.
[57]
GROSSAUER A, MÜLLER C, HUSSL A, et al. Improved diagnostic performance of susceptibility-weighted imaging with[J]. Mov Disord Clin Pract, 2023, 10(6): 914-921 . DOI: 10.1002/mdc3.13736.
[58]
LEE D H, HEO H, SUH C H, et al. Improved diagnostic performance of susceptibility-weighted imaging with compressed sensing-sensitivity encoding and neuromelanin-sensitive MRI for Parkinson's disease and atypical Parkinsonism[J/OL]. Clin. Radiol, 2024, 79(1): e102-e111 [2025-10-22]. https://doi.org/10.1016/j.crad.2023.09.019. DOI: 10.1016/j.crad.2023.09.019.
[59]
MATSUURA K, II Y, MAEDA M, et al. Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for Parkinsonism or neurodegenerative disease affecting the basal ganglia[J]. Parkinsonism Relat Disord, 2021, 87: 75-81 . DOI: 10.1016/j.parkreldis.2021.05.002.
[60]
YOSHIMATSU Y, IDE S, OGAWA N, et al. Utility of locus coeruleus signal intensity on high-resolution T1-weighted MR imaging with magnetization transfer for differentiating Parkinson's disease from atypical Parkinsonism[J/OL]. Magn Reson Med Sci, 2025: mp.2025-126 [2025-10-22]. https://doi.org/10.2463/mrms.mp.2025-0126. DOI: 10.2463/mrms.mp.2025-0126.
[61]
CHOUGAR L, ARSOVIC E, GAURAV R, et al. Regional selectivity of neuromelanin changes in the substantia nigra in atypical Parkinsonism[J]. Mov Disord, 2022, 37(6): 1245-1255 . DOI: 10.1002/mds.28988.
[62]
WHITWELL J L, HÖGLINGER G U, ANTONINI A, et al. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?[J]. Mov Disord, 2017, 32(7): 955-971 . DOI: 10.1002/mds.27038.
[63]
REN Q, WANG Y, LENG S, et al. Substantia nigra radiomics feature extraction of Parkinson's disease based on magnitude images of susceptibility-weighted imaging[J/OL]. Front Neurosci, 2021, 15: 646617 [2025-10-22]. https://doi.org/10.3389/fnins.2021.646617. DOI: 10.3389/fnins.2021.646617.
[64]
BIAN J, WANG X, HAO W, et al. The differential diagnosis value of radiomics-based machine learning in Parkinson's disease: a systematic review and meta-analysis[J/OL]. Front. Aging Neurosci, 2023, 15: 1199826 [2025-10-22]. https://doi.org/10.3389/fnagi.2023.1199826. DOI: 10.3389/fnagi.2023.1199826.
[65]
JOKAR M, JIN Z, HUANG P, et al. Diagnosing Parkinson's disease by combining neuromelanin and iron imaging features using an automated midbrain template approach[J/OL]. Neuroimage, 2023, 266: 119814 [2025-10-22]. https://doi.org/10.1016/j.neuroimage.2022.119814. DOI: 10.1016/j.neuroimage.2022.119814.
[66]
HARTONO S, CHEN R C, WELTON T, et al. Quantitative iron-neuromelanin MRI associates with motor severity in Parkinson's disease and matches radiological disease classification[J/OL]. Front. Aging Neurosci, 2023, 15: 1287917 [2025-10-22]. https://doi.org/10.3389/fnagi.2023.1287917. DOI: 10.3389/fnagi.2023.1287917.
[67]
OH Y, KIM J S, LYOO C H, et al. Spatiotemporal progression patterns of dopamine availability and deep gray matter volume in Parkinson disease-related cognitive impairment[J/OL]. Neurology, 2024, 103(2): e209498 [2025-10-22]. https://doi.org/10.1212/WNL.0000000000209498. DOI: 10.1212/WNL.0000000000209498.
[68]
GAURAV R, VALABRÈGUE R, YAHIA-CHÉRIF L, et al. NigraNet: an automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network[J/OL]. Neuroimage, Clin, 2022, 36: 103250 [202510-16]. https://doi.org/10.1016/j.nicl.2022.103250. DOI: 10.1016/j.nicl.2022.103250.
[69]
SHAFF N, ERHARDT E, NITSCHKE S, et al. Comparison of automated and manual quantification methods for neuromelanin‐sensitive MRI in Parkinson's disease[J/OL]. Hum Brain Mapp, 2023, 45(1): e26544 [2025-10-22]. https://doi.org/10.1002/hbm.26544. DOI: 10.1002/hbm.26544.
[70]
VAILLANCOURT D E, BARMPOUTIS A, WU S S, et al. Automated imaging differentiation for Parkinsonism[J]. JAMA Neurol, 2025, 82(5): 495-505 . DOI: 10.1001/jamaneurol.2025.0112.

PREV Diagnostic value and clinical application progress of multimodal PET-MRI in the prodromal stage of Parkinson<sup><sup>,</sup></sup>s disease
NEXT Research progress of multimodal magnetic resonance imaging in occupational manganese exposure-induced neurotoxicity
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn